Weight loss

#Financing #Helicore Biopharma #Monoclonal antibodies #Obesity #Weight loss

Obesity drug developer emerges from stealth with a $65m financing

Helicore Biopharma has announced its emergence from stealth mode with $65 million in Series A financing, co-led by founding investor Versant Ventures and by OrbiMed.  The company is focused on the discovery and development of first-in-class glucose-dependent insulinotropic peptide (GIP) antagonists for obesity and related conditions.  Helicore’s most advanced asset,… Read More

#Business & Investment #News

Scales showing a comparison between Mounjaro and Ozempic
#Eli Lilly #GLP-1 #Obesity #Phase III trial #Weight loss

New data show Zepbound/Mounjaro superior to Wegovy for weight loss

Eli Lilly’s Zepbound/Mounjaro (tirzepatide) provided a 47% greater relative weight loss compared to Wegovy (semaglutide, also known as Ozempic), according to topline results from the SURMOUNT-5 Phase IIIb clinical trial.  On average, Zepbound led to a superior weight loss of 20.2% compared to 13.7% with Wegovy. … Read More

#News #Trending News

#Artificial intelligence (AI) #CAR-T #Drug discovery #Exosomes #Oncology #Weight loss

New DDW Highlights podcast: 9 December 2024

The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week’s leading news stories all shine a light on… Read More

#News

#Artificial intelligence (AI) #CAR-T #Drug discovery #Exosomes #Oncology #Weight loss

This week in drug discovery (2-6 December) 

News round-up for 2-6 December by DDW Senior Digital Content Editor Diana Spencer. This week’s leading news stories all shine a light on innovation within drug discovery, including a potential ‘best-in-industry’ weight loss drug, a gold-based compound that shrinks tumours by 82%, and a second-generation CAR-T therapy. Read More

#News

Woman standing on scales
#Antag Therapeutics #Financing #Obesity #Weight loss

€80 million financing will advance GIPR drugs for obesity

Biopharmaceutical company Antag Therapeutics has announced the closing of an €80 million Series A financing.   The round was led by Versant Ventures, with participation from Novo Holdings, SR One, Dawn Biopharma (a platform controlled by KKR), Pictet, Longview Ventures (an affiliate of Broadview Ventures), and Export and Investment Fund of… Read More

#Business & Investment #News

Weight loss concept
#Mouse models #Obesity #Skye Bioscience #Therapeutic Antibodies #Weight loss

Significant weight loss with novel CB1-inhibiting antibody

Skye Bioscience has announced preliminary data from a diet-induced obesity (DIO) model in mice, in which its CB1-inhibiting antibody, nimacimab, achieved dose-dependent weight loss of up to 16% compared to vehicle. Skye developed a DIO model using a transgenic mouse expressing the human CB1 receptor… Read More

#News

Woman standing on scales
#Jagiellonian University Medical College #Mitochondria #MitoRX Therapeutics #Obesity #University of Exeter #Weight loss

New drug for obesity reduced weight gain by 32%

Therapies that deliver hydrogen sulphide to cells could one day become the basis of new treatments for obesity and related diseases, new research has concluded. Mounting evidence suggests that hydrogen sulphide plays an important role in the liver. Previous research shows that tiny amounts of hydrogen… Read More

#News

#Antag Therapeutics #FDA #GLP-1 #Obesity #Phase I trial #Weight loss

FDA clears GIP receptor agonist trial in obese subjects

The US Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application for Antag Therapeutics’ lead molecule AT-7687 for obesity. The company has announced plans to initiate a Phase I clinical trial, which will evaluate the safety, tolerability, and pharmacokinetics of AT-7687 in both healthy lean and… Read More

#News #Regulatory

Ozempic Insulin injection pen
#Diabetes #GLP-1 #Neuroscience #Obesity #Society for Neuroscience #Weight loss

News from SfN’s Neuroscience 2024: The brain on GLP-1 agonists

Diabetes and weight loss drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists have widespread effects in the brain, with new research presented at the Society for Neuroscience’s Neuroscience 2024 uncovering potential novel therapeutic benefits and behavioural side effects. About one in eight adults… Read More

#News #Trending News

Weight loss concept
#Diabetes #GLP-1 #Obesity #Weight loss

GLP-1 receptor agonists: Buying into the hype

As further news comes out about the benefits that the diabetes and weight-loss drug Ozempic offers patients, it’s hard not to get caught up in the hype surrounding a therapy many are calling a 'wonder drug'. Of course, it’s not the first time the pharmaceutical industry has produced a therapy… Read More

#Exclusive Content

Dorte Gram
#Fundraising #GLP-1 #Novo Nordisk #Obesity #Pila Pharma #Weight loss

Scientist who discovered Ozempic to study new obesity drug

Dorte Gram, founder of Pila Pharma and a former Novo Nordisk researcher who identified the molecule that became semaglutide, the active ingredient in Ozempic and Wegovy, has raised 10 million SEK ($980,320) for a novel obesity-related study. The money will allow the company to study drug… Read More

#News

Ozempic (semaglutide)
#Cardiovascular disease #Covid-19 #Diabetes #GLP-1 #Weight loss

Semaglutide reduces risk of all-cause death

Semaglutide has been found to reduce the rates of all-cause death, including as a result of Covid-19, in those who are overweight or have obesity and established cardiovascular disease without diabetes. The findings were published in JACC, the journal of the American College… Read More

#News #Trending News

Monoclonal antibodies
#GLP-1 #Monoclonal antibodies #Obesity #Phase II trial #Skye Bioscience #Weight loss

Monoclonal antibody CB1 inhibitor for obesity enters Phase II trials

Skye Bioscience has started screening patients for a Phase II clinical trial (CBeyond) of its novel peripheral CB1 inhibitor, nimacimab, a negative allosteric modulating antibody. The study will assess the ability of nimacimab as a next-generation weight loss therapeutic to safely and effectively reduce weight in… Read More

#Editor's Choice #News

Human heart
#Cardiovascular disease #GLP-1 #Heart failure #Obesity #University College London #Weight loss

Semaglutide could also benefit patients with heart failure

A new study indicates that anti-obesity drug semaglutide helps prevent cardiac events among overweight people who have cardiovascular disease, even if they also have heart failure. The results follow a previous finding that weekly injections of semaglutide were linked to a 20% reduction in major adverse cardiac events (MACE) such… Read More

#News #Trending News

Patient injects Ozempic
#Adverse event #Diabetes #GLP-1 #Obesity #Weight loss

Semaglutide found to increase risk of suicidal thoughts

A new study has suggested a link between semaglutide (the active ingredient in Wegovy and Ozempic) and a disproportionately increased reporting of suicidality. Semaglutide has recently been treated as something of a wonder drug, with studies demonstrating it can reduce the risk of cardiovascular disease,… Read More

#News #Trending News

Woman tests blood glucose level
#Diabetes #Eli Lilly #GLP-1 #Obesity #Phase III trial #Weight loss

Weight loss drug reduced type 2 diabetes risk by 94%

Topline results from the SURMOUNT-1 three-year study have shown that tirzepatide (Zepbound and Mounjaro) significantly reduced the risk of progression to type 2 diabetes by 94% among adults with pre-diabetes and obesity or overweight. Additionally, treatment with tirzepatide resulted in sustained weight loss through the treatment… Read More

#News